IMAGE Syndrome — an acronym for Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal hypoplasia congenita, Genital abnormalities in males, and Enteropathy, with OMIM entry #614732, an ultra-rare condition with fewer than 50 families described in the published literature, caused by heterozygous gain-of-function mutations in CDKN1C (encoding the cyclin-dependent kinase inhibitor p57KIP2, encoded at chromosome 11p15.5 in the maternally expressed imprinted domain) — a genetic mechanism that is the precise molecular opposite of the loss-of-function CDKN1C mutations that cause Beckwith-Wiedemann Syndrome (BWS); in BWS, loss of p57KIP2 activity removes a brake on cell proliferation, producing overgrowth; in IMAGE Syndrome, gain-of-function CDKN1C mutations in the PCNA-binding domain of p57KIP2 generate a hyperactive p57KIP2 protein with enhanced CDK inhibitory activity that constitutively brakes cell proliferation in adrenal, gonadal, intestinal, and growth plate progenitor cells during fetal organogenesis, producing growth failure and organ hypoplasia rather than overgrowth; the specific molecular target of IMAGE-causing CDKN1C mutations is the PCNA-binding domain (proliferating cell nuclear antigen binding domain) — mutations in this domain generate a p57KIP2 protein that forms more stable complexes with PCNA, more potently inhibits CDK2 and CDK1, and more effectively arrests the G1-to-S phase transition in proliferating progenitor cells, explaining the fetal-stage growth restriction rather than the postnatal overgrowth characteristic of BWS loss-of-function mutations; the defining clinical features of IMAGE Syndrome are: severe intrauterine growth restriction (IUGR) detected prenatally with birth weights typically well below the 10th percentile and often below the 3rd percentile; metaphyseal dysplasia — widening, irregularity, and splaying of the metaphyses of long bones (femur, tibia, radius, ulna) detectable on skeletal radiographic survey, reflecting disrupted endochondral ossification in the growth plate where p57KIP2 hyperactivity arrests chondrocyte progenitor proliferation; adrenal hypoplasia congenita (AHC) — the most medically critical feature, producing life-threatening primary adrenal insufficiency in the neonatal period from insufficient adrenal cortical development, with salt-wasting adrenal crisis presenting with hyponatremia, hyperkalemia, hypoglycemia, vomiting, poor feeding, and cardiovascular collapse if glucocorticoid and mineralocorticoid replacement therapy is not initiated immediately; genital abnormalities in male patients — hypospadias, cryptorchidism, and genital hypoplasia reflecting gonadal development impairment; and enteropathy — malabsorption, protein-losing enteropathy, and diarrhea in some patients reflecting intestinal epithelial progenitor proliferation impairment; inheritance follows the imprinting rules at 11p15.5: IMAGE-causing gain-of-function CDKN1C mutations are transmitted on the maternal chromosome (the expressed allele), so IMAGE Syndrome follows maternal transmission or de novo occurrence on the maternal allele, with paternal-allele mutations being clinically silent due to paternal imprinting of CDKN1C.
IMAGE Syndrome technology platforms — encompassing the neonatal intensive care, pediatric endocrinology, and clinical genetics platforms where the combination of severe IUGR, neonatal salt-wasting crisis, and metaphyseal dysplasia raises the IMAGE diagnosis and CDKN1C molecular analysis is urgently pursued, the molecular genetic testing platforms where CDKN1C PCNA-binding domain sequencing identifies the gain-of-function mutation (with parental testing to confirm maternal origin for imprinting confirmation), the adrenal crisis emergency alert systems that must detect the physiological deterioration of adrenal insufficiency in IMAGE patients during intercurrent illness and trigger immediate stress-dose hydrocortisone administration before cardiovascular collapse, the endocrinology surveillance scheduling platforms coordinating serial ACTH stimulation testing, plasma ACTH and cortisol monitoring, mineralocorticoid adequacy assessment (renin, aldosterone, electrolytes), and steroid replacement dose adjustment through the growth period, the growth hormone replacement therapy tracking platforms in patients with IMAGE Syndrome who have both short stature and GH deficiency (a common co-occurrence given the CDKN1C-mediated growth plate impairment), the metabolic crisis monitoring systems for hypoglycemia surveillance in the adrenal-insufficient IMAGE patient, the gastroenterology platforms managing IMAGE-associated enteropathy, and the skeletal surveillance platforms documenting metaphyseal dysplasia evolution — must maintain the availability and performance standards required by the life-threatening nature of adrenal crisis in this population, the critical importance of steroid replacement adherence and stress dosing, and the multi-specialty coordination of adrenal, growth, gastrointestinal, and skeletal surveillance that defines modern IMAGE care. This guide explains why IMAGE Syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the adrenal crisis emergency priority, steroid replacement precision, growth hormone tracking, and endocrinological surveillance intensity of this ultra-rare CDKN1C gain-of-function syndrome.
Why IMAGE Syndrome Tech Platforms Require Specialized Monitoring Attention
IMAGE Syndrome management is defined by several life-critical monitoring obligations: the adrenal crisis emergency imperative — primary adrenal insufficiency in IMAGE Syndrome is a life-threatening emergency that can progress from early illness symptoms to cardiovascular collapse within hours if stress-dose hydrocortisone is not administered, making adrenal crisis emergency alert platforms the highest-priority component in the IMAGE care ecosystem; the steroid replacement precision requirement — both glucocorticoid (hydrocortisone) and mineralocorticoid (fludrocortisone) replacement must be precisely dosed, monitored, and adjusted through growth phases, making endocrinology surveillance scheduling platforms clinically critical; the growth hormone replacement therapy tracking obligation — GH deficiency co-occurring with IMAGE short stature requires GH therapy monitoring with careful attention to the hypoglycemia risk of GH-deficient patients; and the neonatal period life-threatening urgency — the initial presentation of IMAGE Syndrome may be a neonatal adrenal crisis in a severely growth-restricted newborn who has not yet been diagnosed, making the diagnostic and emergency management systems simultaneously operative.
Adrenal crisis emergency alert platforms are the highest-priority component in the IMAGE care ecosystem. Adrenal insufficiency in IMAGE patients during febrile illness, surgical procedures, or severe physiological stress can progress to cardiovascular collapse within hours without stress-dose glucocorticoid administration. Monitor adrenal crisis alert systems at 1-minute intervals, 24/7.
Endocrinology surveillance scheduling platforms coordinate the steroid replacement monitoring obligations. Serial ACTH stimulation testing, plasma cortisol, renin-aldosterone-electrolyte panels, and hydrocortisone dose adjustment require reliable scheduling platform availability at pediatric intervals. Monitor endocrinology platforms at 1-minute intervals during clinic hours.
Metabolic crisis monitoring systems detect hypoglycemia in the adrenal-insufficient IMAGE patient. Glucocorticoid deficiency produces fasting hypoglycemia and stress hypoglycemia; continuous glucose monitoring or structured glucose surveillance in IMAGE patients requires reliable platform availability. Monitor metabolic monitoring systems at 1-minute intervals, 24/7 for acute monitoring and during clinic hours for scheduled surveillance.
Growth hormone therapy tracking platforms monitor GH replacement in IMAGE patients with GH deficiency. Height velocity response to GH treatment, IGF-1 levels, dose adjustment, and compliance monitoring require reliable platform availability at pediatric endocrinology intervals. Monitor GH tracking platforms at 1-minute intervals during clinic hours.
Molecular genetic testing platforms urgently confirm the IMAGE diagnosis in neonates with adrenal crisis. CDKN1C gain-of-function mutation identification distinguishes IMAGE Syndrome from other causes of adrenal hypoplasia congenita (DAX1/NR0B1 mutations, STAR mutations, CYP11A1 mutations) and determines the imprinting mechanism for genetic counseling. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
What to Monitor on an IMAGE Syndrome Tech Platform
Molecular Genetic Testing — CDKN1C PCNA-Binding Domain Sequencing
Monitor genetic testing referral records (clinical suspicion documentation — severe IUGR with neonatal salt-wasting adrenal crisis and metaphyseal dysplasia on skeletal survey, male genital anomalies, enteropathy, differential diagnosis of adrenal hypoplasia congenita including DAX1/NR0B1 exclusion, clinical urgency designation for neonatal crisis setting), CDKN1C molecular testing records (targeted sequencing of CDKN1C PCNA-binding domain — gain-of-function missense mutation identification, distinction from BWS-associated loss-of-function CDKN1C mutations, methylation analysis at 11p15.5 imprinted domain to assess methylation status), parental origin analysis records (maternal versus paternal origin of the CDKN1C mutation — maternal transmission confirmation for imprinting mechanism, de novo maternal allele mutation documentation for recurrence risk counseling), 11p15.5 imprinting domain methylation testing records, genetic counseling records (maternal inheritance pattern, 50% recurrence risk if maternal carrier, de novo mutation counseling), and report transmission records at 1-minute intervals during laboratory hours. Alert immediately — CDKN1C sequencing platform failures during the emergency evaluation of a 5-day-old neonate with severe salt-wasting adrenal crisis, birth weight at 1.4 kg with severe IUGR, and metaphyseal widening on radiograph delay the molecular confirmation that distinguishes IMAGE Syndrome from DAX1 deficiency and determines the specific genetic counseling and family testing pathway while immediate steroid replacement has already been initiated empirically.
Adrenal Crisis Emergency Alert Systems
Monitor adrenal crisis emergency alert records (illness protocol trigger documentation — fever >38.5°C, vomiting preventing oral hydrocortisone, significant physiological stress triggering 3× stress-dose hydrocortisone oral or IM injection protocol initiation), adrenal crisis emergency kit records (intramuscular hydrocortisone kit prescription, dispense confirmation, kit location documentation for home, school, and respite care settings, caregiver training completion records), emergency department communication records (adrenal insufficiency emergency card — available to emergency physicians 24/7 documenting IMAGE diagnosis, baseline steroid replacement doses, stress dosing protocol, IV hydrocortisone dose for severe crisis), adrenal crisis event documentation records (crisis severity, trigger identification, time to stress-dose administration, response to therapy, hospitalization requirement, crisis management review), and physiological deterioration detection records (vital sign threshold alerts — heart rate, blood pressure, glucose — in monitored IMAGE patients triggering clinical assessment for adrenal crisis) at 1-minute intervals, 24/7. Alert immediately — adrenal crisis emergency alert platform failures for an IMAGE patient whose febrile gastroenteritis prevents oral hydrocortisone absorption and whose caregiver cannot access the IM injection protocol documentation leave the patient without the stress-dose initiation guidance that prevents cardiovascular collapse from glucocorticoid-deficient physiological stress response.
Endocrinology Surveillance — Steroid Replacement Monitoring
Monitor glucocorticoid replacement monitoring records (hydrocortisone total daily dose per m² body surface area, dose distribution across day — typically 3 divided doses reflecting cortisol diurnal rhythm, dose adequacy markers — growth velocity, bone age, body composition, symptoms of over-replacement including growth suppression and Cushingoid features versus under-replacement including fatigue, hypoglycemia, salt craving), mineralocorticoid replacement monitoring records (fludrocortisone dose, blood pressure supine and standing, serum sodium and potassium, plasma renin activity — elevated renin indicating mineralocorticoid under-replacement, hypernatremia/hypertension indicating over-replacement), ACTH and cortisol records (plasma ACTH — typically markedly elevated in primary adrenal insufficiency, used to confirm adequacy of glucocorticoid replacement rather than to diagnose ongoing crisis; morning cortisol pre-dose confirming absent endogenous cortisol production), annual or biannual complete endocrine review records (adrenal function reassessment, puberty staging in adolescent patients — IMAGE patients may have HPA axis function assessed at adrenarche age), and dose adjustment records (growth-related dose increase, illness-related stress dose documentation, surgery preparation records including stress dosing protocol activation) at 1-minute intervals during clinic hours. Alert immediately — steroid replacement monitoring platform failures delaying the annual endocrine review for a 9-year-old IMAGE patient interrupt the hydrocortisone dose per m² recalculation required as the child grows, creating the risk of relative under-replacement as body surface area increases with normal somatic growth while the dose remains at the prior year's level.
Growth Hormone Replacement Therapy Tracking
Monitor GH deficiency evaluation records (GH stimulation testing — glucagon or arginine stimulation test, peak GH response below threshold confirming GH deficiency in IMAGE patient; IGF-1 and IGFBP-3 at baseline; thyroid function testing to exclude hypothyroidism before GH axis assessment), GH therapy records (daily subcutaneous GH injection dose per kg per day, device type — pen injector or needle-free device, injection site rotation, adherence monitoring), GH therapy monitoring records (height velocity at 3-monthly intervals during GH initiation year, annual height velocity and height SD score thereafter, IGF-1 at target range, bone age annually to assess skeletal maturation rate relative to chronological age), hypoglycemia surveillance records (IMAGE patients with adrenal insufficiency and GH deficiency have compounded hypoglycemia risk — continuous glucose monitoring or structured fasting glucose surveillance, nocturnal hypoglycemia monitoring), GH therapy complication monitoring records (intracranial hypertension symptoms, scoliosis progression surveillance, and slipped capital femoral epiphysis monitoring), and GH treatment outcome records (final adult height versus predicted adult height at initiation, GH treatment discontinuation at growth plate closure documentation) at 1-minute intervals during clinic hours. Alert immediately — GH therapy tracking platform failures for an IMAGE patient on GH replacement interrupt the IGF-1 safety monitoring that ensures the GH dose is achieving target IGF-1 levels without exceeding the safe range in the context of adrenal insufficiency where GH excess could compound the hypoglycemia risk.
Metabolic Crisis Monitoring — Hypoglycemia Surveillance
Monitor blood glucose monitoring records (structured fasting glucose and post-prandial glucose in IMAGE patients with adrenal insufficiency, continuous glucose monitoring data in patients with recurrent hypoglycemia or high-risk periods — illness, overnight fasting), hypoglycemia event records (plasma glucose <70 mg/dL symptomatic or <54 mg/dL any — event documentation, symptom characterization, timing relative to steroid doses, management — oral glucose, glucagon, IV dextrose, trigger identification), hypoglycemia protocol records (home glucagon kit prescription and caregiver training completion, hypoglycemia emergency action plan distribution to school and daycare settings), and electrolyte monitoring records (sodium, potassium — mineralocorticoid adequacy assessment and adrenal crisis early detection) at 1-minute intervals during acute monitoring periods and clinic hours for scheduled surveillance. Alert immediately — metabolic monitoring platform failures during a febrile illness monitoring period for an IMAGE patient interrupt the glucose surveillance that detects the adrenal insufficiency-driven hypoglycemia triggering stress-dose escalation.
Gastrointestinal and Skeletal Surveillance
Monitor enteropathy management records (protein-losing enteropathy assessment — serum albumin, prealbumin, total protein; stool alpha-1-antitrypsin; enteral nutrition support prescription; gastrointestinal symptom tracking — diarrhea frequency, growth faltering correlation), skeletal radiographic survey records (metaphyseal dysplasia documentation — annual or biannual long bone radiographs documenting metaphyseal widening at femur, tibia, radius, ulna; growth plate morphology; interval comparison), and multi-specialty coordination records (combined endocrinology-gastroenterology-orthopedics-genetics review scheduling platforms) at 1-minute intervals during clinic hours.
Authentication and SSL
Monitor authentication at 1-minute intervals, 24/7. IMAGE Syndrome care coordinates across neonatology (initial adrenal crisis management), pediatric endocrinology (steroid replacement, GH therapy), clinical genetics (CDKN1C diagnosis), gastroenterology (enteropathy), radiology (metaphyseal dysplasia), metabolic medicine (hypoglycemia), and rare disease coordination — authentication failures block the adrenal crisis emergency response and multi-specialty management that define IMAGE care. Monitor SSL certificate expiry across all genetic testing platforms, adrenal crisis alert systems, endocrinology scheduling platforms, GH tracking systems, and metabolic monitoring portals with 30-day advance warning.
HIPAA and Ultra-Rare Disease Patient Privacy Considerations
IMAGE Syndrome technology platforms handle highly sensitive PHI including neonatal adrenal crisis records, CDKN1C molecular genetic testing with imprinting mechanism analysis (heritable through maternal line with 50% recurrence), lifetime steroid replacement prescriptions, growth hormone therapy records, hypoglycemia monitoring data, and metabolic crisis event documentation. The ultra-rare prevalence (fewer than 50 families globally) makes patient identification risk extreme in regional databases. The heritable nature of maternal-transmitted CDKN1C gain-of-function mutations creates GINA obligations alongside HIPAA requirements.
Alerting Strategy for IMAGE Syndrome Tech Platforms
Immediate 24/7 alerting for adrenal crisis emergency alert platforms: Adrenal insufficiency crisis in IMAGE patients is a life-threatening emergency at any hour. Emergency kit access, stress-dose protocols, and emergency department communication platforms must be available 24/7 without exception.
Immediate 24/7 alerting for metabolic crisis monitoring during acute illness: Hypoglycemia and electrolyte crisis surveillance in the context of febrile illness requires round-the-clock monitoring platform availability.
Immediate laboratory-hours alerting for CDKN1C molecular testing: Rapid molecular confirmation in neonatal adrenal crisis settings determines genetic counseling and differentiates IMAGE from other AHC causes.
Immediate clinic-hours alerting for endocrinology surveillance: Steroid replacement dose monitoring, mineralocorticoid adequacy assessment, and GH therapy monitoring cannot be delayed by scheduling platform failures.
Sustained-failure alert (10–15 minutes): Patient registry platforms and rare disease coordination networks.
30-day advance warning: SSL certificates across all domains.
Status Page for IMAGE Syndrome Care Team Communication
A real-time status page gives pediatric endocrinologists adjusting hydrocortisone and fludrocortisone doses, molecular geneticists confirming CDKN1C gain-of-function mutations, emergency physicians accessing adrenal crisis protocols, pharmacists dispensing IM hydrocortisone emergency kits, and gastroenterologists managing enteropathy immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in adrenal crisis emergency protocols, steroid replacement home management plans, and school emergency action plans distributed to educational settings for IMAGE patients.
Vigilmon Setup for IMAGE Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Adrenal crisis emergency alert platform | 1 min | Slack + PagerDuty (24/7) | | Adrenal crisis IM kit access and protocol portal | 1 min | Slack + PagerDuty (24/7) | | Metabolic crisis monitoring (glucose/electrolytes) | 1 min | Slack + PagerDuty (24/7 acute) | | CDKN1C PCNA-binding domain sequencing | 1 min | Slack + PagerDuty (lab hours) | | Imprinting methylation analysis (11p15.5) | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and parental testing | 1 min | Slack + PagerDuty (lab hours) | | Hydrocortisone dose monitoring (mg/m²/day) | 1 min | Slack + PagerDuty (clinic hours) | | Fludrocortisone and mineralocorticoid adequacy | 1 min | Slack + PagerDuty (clinic hours) | | ACTH and cortisol steroid monitoring | 1 min | Slack + PagerDuty (clinic hours) | | GH deficiency evaluation and GH therapy tracking | 1 min | Slack + PagerDuty (clinic hours) | | IGF-1 safety monitoring (GH therapy) | 1 min | Slack + PagerDuty (clinic hours) | | Enteropathy management and nutrition support | 1 min | Slack + PagerDuty (clinic hours) | | Metaphyseal dysplasia skeletal survey scheduling | 2 min | Slack (clinic hours) | | IMAGE patient registry | 2 min | Slack (business hours) | | Rare disease coordination network | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure adrenal crisis emergency alert platform with 24/7 immediate alerting — this is the absolute highest priority in IMAGE care
- Add adrenal crisis IM kit access and protocol portal with 24/7 immediate alerting
- Configure metabolic crisis monitoring (glucose/electrolyte) with 24/7 immediate alerting for acute illness periods
- Add CDKN1C molecular testing with immediate laboratory-hours alerting
- Configure imprinting methylation analysis platforms with immediate laboratory-hours alerting
- Add genetic counseling and parental origin testing with immediate laboratory-hours alerting
- Configure hydrocortisone dose monitoring with immediate clinic-hours alerting
- Add fludrocortisone and mineralocorticoid adequacy platforms with immediate clinic-hours alerting
- Configure ACTH and cortisol steroid monitoring with immediate clinic-hours alerting
- Add GH therapy tracking and IGF-1 safety monitoring with immediate clinic-hours alerting
- Configure enteropathy management and nutrition support platforms with immediate clinic-hours alerting
- Add skeletal survey scheduling with sustained-failure alerting during clinic hours
- Configure patient registry and rare disease coordination with sustained-failure alerting
- Enable SSL certificate monitoring across all genetic testing, emergency, endocrinology, and GH tracking platforms
- Add the status page URL to adrenal crisis protocols, school emergency action plans, and steroid replacement home management documents
Conclusion
IMAGE Syndrome technology platforms are embedded in clinical decisions where adrenal crisis emergency alert platform availability for a 4-year-old with IMAGE Syndrome who develops a febrile illness with vomiting at 11:30 PM on a Saturday — when the parents cannot reach the on-call endocrinologist and need to access the digital stress-dose protocol that tells them when and how to administer the emergency IM hydrocortisone kit stored in the home, and need the adrenal crisis emergency card available on their phone to show to the emergency department physician who has never seen an IMAGE patient and does not know that this child's salt-wasting adrenal insufficiency means that IV hydrocortisone 50 mg/m² must be administered within the next 30 minutes to prevent the cardiovascular collapse that follows uncorrected glucocorticoid deficiency during the physiological stress of febrile illness — cannot be disrupted by emergency platform failures that leave the parents and the emergency physician without access to the adrenal crisis management protocol that keeps this child alive; where steroid replacement monitoring platform availability for the same child's annual endocrinology review — when the endocrinologist needs the prior year's growth velocity and body surface area measurements to recalculate the hydrocortisone dose per m² that has been inadequate since the child grew 5 cm and gained 3 kg since the last dose adjustment, producing the relative glucocorticoid under-replacement that explains the subtle fatigue, mild hypoglycemia tendency, and slightly elevated morning ACTH that the parents have been noting for the past 2 months — cannot be disrupted by scheduling platform failures that delay the dose recalculation that corrects the relative under-replacement before it produces a overt adrenal crisis during the next intercurrent illness; and where GH therapy tracking platform availability for an 8-year-old IMAGE patient 18 months into GH replacement therapy — when the quarterly IGF-1 level needs to be reviewed alongside the height velocity response to confirm that the current GH dose is achieving therapeutic IGF-1 levels without exceeding the safe range in the context of the adrenal insufficiency background where GH excess would compound hypoglycemia risk — cannot be disrupted by tracking platform failures that leave the endocrinologist without the IGF-1 trend data required to make the safe dose adjustment. An adrenal crisis emergency platform unavailable during a febrile illness when stress-dose administration prevents cardiovascular collapse, a steroid replacement monitoring system down when relative under-replacement must be identified and corrected before the next illness crisis, a GH tracking platform inaccessible when IGF-1-guided dose adjustment must balance efficacy against hypoglycemia risk — these are not IT incidents. They are clinical failures in the management of an ultra-rare CDKN1C gain-of-function syndrome whose adrenal crisis risk, steroid replacement precision, and growth hormone monitoring intensity make platform availability a literal life-safety requirement.
Uptime monitoring gives IMAGE Syndrome care tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pediatric endocrinologists, emergency physicians, molecular geneticists, specialty pharmacists, and compliance auditors that platform operational reliability matches the adrenal crisis emergency urgency, steroid replacement precision, and growth hormone monitoring obligations of modern IMAGE Syndrome care.
Start monitoring your IMAGE Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #IMAGE #syndrome #CDKN1C #p57KIP2 #adrenal #hypoplasia #congenita #adrenal #crisis #hydrocortisone #fludrocortisone #steroid #replacement #GH #therapy #IGF1 #metaphyseal #dysplasia #IUGR #imprinting #11p15 #rare #genetic #disorder #HIPAA #healthtech #digitalhealth #uptime #sre